Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab

• Published in: BMC ophthalmology 2017-08, Vol.17 (1), p.147-147, Article 147
• Main Authors: Gonzalez-Buendia, Lucia, Delgado-Tirado, Santiago, Sanabria, M Rosa, Fernandez, Itziar, Coco, Rosa M
• Format: Article
• Language: English
• Subjects: Age; Age-related macular degeneration; Aged; Aged, 80 and over; Analysis; Angiogenesis Inhibitors - therapeutic use; Animal models; Anti-VEGF; Atrophy; Care and treatment; Cataracts; Choroidal neovascularization; Choroidal Neovascularization - drug therapy; Diagnosis; Drug dosages; Epithelium; Eye; Female; Fibrosis; Geographic Atrophy - etiology; Humans; Immunotherapy; Information theory; Intravitreal Injections; Macula Lutea - pathology; Macular degeneration; Macular Degeneration - diagnosis; Macular Degeneration - drug therapy; Macular Degeneration - pathology; Male; Mathematical statistics; Medical imaging; Middle Aged; Monoclonal antibodies; Ophthalmology; Patients; Predictive Value of Tests; Ranibizumab - therapeutic use; Risk Factors; Sensitivity and Specificity; Statistical analysis; Statistics; Variables; Vascular endothelial growth factor; Vision; Visual Acuity
• ISSN: 1471-2415; 1471-2415
• DOI: 10.1186/s12886-017-0544-x

To analyze predictors and develop predictive models of anatomic outcome in neovascular age-related macular degeneration (AMD) treated with as-needed ranibizumab after 4 years of follow-up. A multicenter consecutive case series non-interventional study was performed. Clinical, funduscopic and OCT characteristics of 194 treatment-naïve patients with AMD treated with as-needed ranibizumab for at least 2 years and up to 4 years were analyzed at baseline, 3 months and each year until the end of the follow-up. Baseline demographic and angiographic characteristics were also evaluated. R Statistical Software was used for statistical analysis. Main outcome measure was final anatomic status. Factors associated with less probability of preserved macula were diagnosis in 2009, older age, worse vision, presence of atrophy/fibrosis, pigment epithelium detachment, and geographic atrophy/fibrotic scar/neovascular AMD in the fellow eye. Factors associated with higher probability of GA were presence of atrophy and greater number of injections, whereas male sex, worse vision, lesser change in central macular thickness and presence of fibrosis were associated with less probability of GA as final macular status. Predictive model of preserved macula vs. GA/fibrotic scar showed sensibility of 77.78% and specificity of 69.09%. Predictive model of GA vs. fibrotic scar showed sensibility of 68.89% and specificity of 72.22%. We identified predictors of final macular status, and developed two predictive models. Predictive models that we propose are based on easily harvested variables, and, if validated, could be a useful tool for individual patient management and clinical research studies.